Molecular Epidemiology of Infant Botulism in California and Elsewhere, 1976–2010

Haydee A. Dabritz,1,## Karen K. Hill,2 Jason R. Barash,1 Lawrence O. Ticknor,3 Charles H. Helma,2 Nir Dover,1 Jessica R. Payne,1 and Stephen S. Arnon1

1Infant Botulism Treatment and Prevention Program, Division of Communicable Disease Control, Center for Infectious Diseases, California Department of Public Health, Richmond; 2Bioscience Division, and 3Computing, Computational and Statistical Sciences Division, Los Alamos National Laboratory, New Mexico

Background. Infant botulism (IB), first identified in California in 1976, results from Clostridium botulinum spores that germinate, multiply, and produce botulinum neurotoxin (BoNT) in the immature intestine. From 1976 to 2010 we created an archive of 1090 BoNT-producing isolates consisting of 1012 IB patient (10 outpatient, 985 hospitalized, 17 sudden death), 25 food, 18 dust/soils, and 35 other strains.

Methods. The mouse neutralization assay determined isolate toxin type (56% BoNT/A, 32% BoNT/B). Amplified fragment-length polymorphism (AFLP) analysis of the isolates was combined with epidemiologic information.

Results. The AFLP dendrogram, the largest to date, contained 154 clades; 52% of isolates clustered in just 2 clades, 1 BoNT/A (n = 418) and 1 BoNT/B (n = 145). These clades constituted an endemic C. botulinum population that produced the entire clinical spectrum of IB. Isolates from the patient’s home environment (dust/soil, honey) usually located to the same AFLP clade as the patient’s isolate, thereby identifying the likely source of infective spores. C. botulinum A(B) strains were identified in California for the first time.

Conclusions. Combining molecular methods and epidemiological data created an effective tool that yielded novel insights into the genetic diversity of C. botulinum and the clinical spectrum, occurrence, and distribution of IB in California.

Keywords. botulinum toxin; clinical spectrum; Clostridium baratii; Clostridium botulinum; Clostridium butyricum; honey; infant botulism; molecular epidemiology; sudden infant death.
(AFLP) analysis for this study because of its robustness and suitability for examining large collections of C. botulinum isolates [7, 20, 21], together with real-time polymerase chain reaction (RT-PCR) to identify bont subtypes, and combined the molecular results with epidemiologic and clinical information. This combination provided novel and unexpected insights into both the bacterium and the occurrence of IB in California and other parts of North America in the past 35 years.

METHODS

Case Definition, Case Identification, and Collection of Epidemiologic Data

An IB case was defined as an infant with symptoms consistent with the known paralyzing action of BoNT, including sudden death, in which BoNT or C. botulinum was identified in intestinal contents or feces. Cases outside of California were identified through distribution of Human Botulism Immune Globulin Intravenous (BIG-IV; BabyBIG [1]) and had C. botulinum freshly isolated from a second fecal specimen or were identified through the Centers for Disease Control and Prevention (CDC) national surveillance reports (http://www.cdc.gov/natlssurveillance/botulism-surveillance.html). Cases were assigned to the state and county in which the infant lived for the 2 weeks immediately before onset (defined as the date on which the parent first contacted a medical provider about the symptoms of the illness). The incidence calculations included all US IB cases from 1976 to 2010 and live-births in California by county and nationwide by state, available from the California Department of Public Health (CDPH) at http://www.cdph.ca.gov/data/statistics/Pages/StatewideBirthStatisticalDataTables.aspx (accessed November 8, 2011), and from the National Center for Health Statistics, Hyattsville, MD, at http://www.cdc.gov/nchs/births.htm (accessed December 8, 2011), respectively. Epidemiological data for all California and BIG-IV-treated patients elsewhere were obtained by home visit and/or telephone interview.

Culture and DNA Isolation

Clostridium botulinum was originally isolated from patient and environmental specimens using standard methods [22], frozen at −70°C, and then freshly cultured to create cell pellets for DNA isolation (see online Supplementary Data) that followed the protocol for DNA extraction from Gram-positive bacteria using the Qiagen DNeasy Blood and Tissue Kit.

AFLP Analysis

For AFLP analysis, DNA preparations were digested with 2 restriction enzymes selected for A/T-rich genomes, linkers were ligated to the resulting fragments, and a series of PCR amplifications were performed as previously described [7]. Forty DNA fragment sizes were used to create a genetic fingerprint representing each isolate [23]. Clustering analysis of the fragment sizes for the 1091 isolates created a dendrogram with 154 clades. (The non-toxigenic C. sporogenes ATCC 11437 isolate was part of the collection.) Differences of >0.20 genetic distance units, the error inherent to the method, differentiated the clades from each other. (See online Supplementary Data for details.)

Toxin Gene Characterization by RT-PCR

Six hundred thirty-five type A and type B isolates, 58% of the collection, were characterized by RT-PCR to determine the subtype and presence of an unexpressed (“silent”) bont/B gene (see online Supplementary Data for primers, probes, and conditions used).

Spatial Analysis

Latitude and longitude coordinates were assigned to the patient’s residence address at onset of illness, with ZIP code or city centroid coordinates assigned for nonmatching or missing addresses. For clades with ≥10 isolates, SaTScan (http://www.satscan.org) with a case-control model was used to search for geographic or geographic-temporal clusters within that clade by comparing its IB patient isolates to those of all other California IB patients [24]. Environmental, food, and sudden-death case isolates were excluded from this analysis. Possible geographic-temporal clusters were sought in circular geographic areas of radius ≤125 km and maximum time windows of ≤5 years (see online Supplementary Data for details).

RESULTS

Infant Botulism Occurrence in California and Elsewhere

From 1976 to 2010, 2803 IB cases were reported in the United States; 1093 (39%) occurred in California. Table 1 lists the origins of the 1091 isolates studied. These 1091 isolates included 1012 IB patient isolates: 948 California, 55 other US states, and 9 other countries. These 1012 IB patients included the entire clinical spectrum of IB (ie, 10 outpatient, 985 hospitalized, and 17 sudden-death cases). An additional 79 patient-associated environmental isolates and reference strains were also analyzed. By the mouse neutralization assay, the 1090 neurotoxigenic isolates consisted of 609 (56%) BoNT/A; 345 (32%) BoNT/B; 22 (2%) bivalent BoNT/Af, /Ba, or /Bf; 11 (1%) BoNT/E; 9 (1%) BoNT/F; and 8 (1%) BoNT/C, /D or /G. Eighty-six (8%) strains were A(B) (Table 1).

The distribution of IB cases in California reflected the underlying population, with IB cases generally occurring in or near large population centers in the Los Angeles basin, San Francisco Bay area, and metropolitan San Diego (Figure 1A–D). However, cases also occurred in less populated rural areas. More than half of California IB cases were caused by BoNT/A strains and approximately one-third by BoNT/B strains. In comparison, bivalent and C. baratii BoNT/F strains were rare. IB incidence from 1976 to 2010 was 6.2/100 000 live-births, almost 3-fold higher...
than the nationwide incidence of 2.1/100,000 live-births in the same interval. The annual ratio of BoNT/A to BoNT/B cases in California over the 35-year study was 1.7 (range, 0.7–8.5).

**AFLP Analysis and bont RT-PCR Characterization**

The AFLP dendrogram differentiated the 1091 clostridial isolates into 154 clades, 64 with multiple isolates and 90 with only a single isolate (Figure 2; Supplementary Data Appendix I). A striking feature of the dendrogram was its 2 largest clades, 1 containing 418 BoNT/A isolates (n = 387 California IB patients, Figure 1B) and the other containing 145 BoNT/B isolates (n = 141 California IB patients, Figure 1D). Hence, these 2 clades contained more than half (563; 52%) of all the isolates in the collection and represented the 2 predominant genotypes of *C. botulinum* that have caused IB in California for the past 35 years. The other 528 isolates of the collection located to the 152 other clades within the dendrogram.

The *bont* gene RT-PCR characterization identified subtypes/variants *bont*/A1, /A2, /A4, and *bont*/B1, /B2, /B3, /B4, /B5, and silent B (Figure 2). The Loch Maree BoNT/A3 strain, the only BoNT/A3 isolate in the collection, was included for reference purposes [25, 26]. The 86 A(B) isolates containing the unexpressed *bont*/(B) gene located to 14 clades; 67 isolates were from California IB patients (Figure 3A). Also, a large number of bivalent BoNT/BA (n = 17), and /BF (n = 3) and *C. baratii* type F (n = 2) isolates were obtained from infant botulism cases that occurred in different years and geographic locations in California (Figure 3C).

### Table 1. Source and Geographic Origin of Clostridial Isolates in the AFLP-Based Dendrogram (n = 1091)

<table>
<thead>
<tr>
<th>Source</th>
<th>California</th>
<th>United States (Outside California)</th>
<th>International (Outside United States)</th>
<th>Unknown</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infant botulism&lt;sup&gt;a&lt;/sup&gt;</td>
<td>948</td>
<td>55</td>
<td>9</td>
<td>.</td>
<td>1012</td>
</tr>
<tr>
<td>Honey</td>
<td>13</td>
<td>.</td>
<td>.</td>
<td>.</td>
<td>13</td>
</tr>
<tr>
<td>Other foods</td>
<td>2</td>
<td>7</td>
<td>3</td>
<td>.</td>
<td>12</td>
</tr>
<tr>
<td>Environmental</td>
<td>14&lt;sup&gt;b&lt;/sup&gt;</td>
<td>2</td>
<td>.</td>
<td>.</td>
<td>18</td>
</tr>
<tr>
<td>Foodborne botulism</td>
<td>2</td>
<td>.</td>
<td>.</td>
<td>.</td>
<td>2</td>
</tr>
<tr>
<td>Wound botulism</td>
<td>12</td>
<td>3</td>
<td>.</td>
<td>.</td>
<td>15</td>
</tr>
<tr>
<td>Intestinal toxemia</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>.</td>
<td>4</td>
</tr>
<tr>
<td>Reference strains&lt;sup&gt;c&lt;/sup&gt;</td>
<td>.</td>
<td>5</td>
<td>6</td>
<td>4</td>
<td>15</td>
</tr>
<tr>
<td>Total</td>
<td>992</td>
<td>73</td>
<td>22</td>
<td>4</td>
<td>1091</td>
</tr>
</tbody>
</table>

Abbreviations: AFLP, amplified fragment-length polymorphism; BoNT, botulinum neurotoxin.

<sup>a</sup> Includes 10 outpatient and 17 sudden-death cases.

<sup>b</sup> n = 11 soil, n = 2 vacuum cleaner dust, and n = 1 ceiling fan dust; isolates collected from California IB patient homes.

<sup>c</sup> Includes reference strain *C. sporogenes* ATCC11 437. Note that the bottom 4 rows of the table consist of 35 BoNT-producing isolates and 1 nontoxigenic *C. sporogenes* strain.

3 to a closely related BoNT/A clade, 1 to the largest BoNT/B clade, 1 to the largest A(B) clade, and 1 to a small BoNT/A clade. Twelve of the 17 sudden-death cases located to the largest BoNT/A clade and 1 to the largest BoNT/B clade (Figure 2; Supplementary Data Appendix I). Hence, both the largest BoNT/A and the largest BoNT/B clades contained *C. botulinum* isolates indistinguishable by AFLP analysis that produced the entire clinical spectrum of infant botulism.

**Clades Associated With Honey Consumption**

The AFLP analysis produced 2 clades that contained isolates both from honeys and from IB patients fed those honeys before onset of illness. The first clade contained 5 BoNT/A2 isolates from 4 patients (1982, 1995, 1997, 2001) and from 1 commercial honey consumed by the 1982 patient. The honeys fed to the other 3 patients were not available for testing. The second clade associated with honey consumption contained 18 patient and 8 honey type B isolates from 1983 to 1988 (Table 2). All 26 isolates were subtyped and determined to be *bont*/B5. Fourteen (78%) of the 18 patients had been fed honey in the month before onset of illness, and 7 of the 8 honey isolates in this clade were from honeys consumed by 6 of the patients. One patient without a history of honey consumption lived in the honey-producing area.

**Clades Associated With Dust and Soils Collected at Patients’ Homes**

*Clostridium botulinum* was isolated from 14 environmental samples from the homes of 8 IB patients (Table 1, footnote b), of which 11 located to the same clade as the patient’s isolate. The co-location of patient and environmental isolate(s) in the same clade included: 1 vacuum cleaner dust and 2 soil isolates from the home of 2 sibling type A patients in an Alameda County city; 1 vacuum cleaner dust and 2 soil isolates from...
Figure 1. Infant botulism cases caused by *C. botulinum* types A and B in California, 1976–2010. A, All BoNT/A IB patient isolates (n = 560), excluding A(B) isolates. B, Isolates in the largest AFLP BoNT/A clade, which contained a type A Hall strain, 383 California hospitalized IB cases, 4 outpatient cases, and 12 sudden-death cases (not included on map). Note that cases occurred in all 35 years of the study period. A geographic but not temporal cluster of radius 35 km was detected near Escondido (San Diego County). C, All BoNT/B IB patient isolates (n = 282). D, The largest AFLP BoNT/B clade (n = 141). Note that cases occurred in all years of the study period except for 1979, 1992, 1993, and 2008. One geographic but not temporal cluster was identified in the Los Angeles area near Anaheim (radius 39 km). Geographic-temporal clustering was determined using the Kulldorff spatial-scan statistic with a case-control model [24]. Abbreviations: AFLP, amplified fragment-length polymorphism; BoNT, botulinum neurotoxin; IB, infant botulism.
Figure 2. Schematic diagram of the AFLP dendrogram of 1091 clostridial isolates. Note that more than half the isolates (52%) located to just 2 large clades, 1 of toxin type A and the other of toxin type B. Note also the wide separation of the 2 major A(B)-containing clades, the bivalent (BoNT/Ba- and /Bf-containing) clades and other BoNT/A- and /B-containing clades. Dendrogram constructed using 40 DNA fragments and a cluster algorithm with the Jaccard distance measure [23]. The full Figure 2 in pdf format may be found in Supplementary Data Appendix I; when the isolates in it are displayed in an 8-point font, the figure measures approximately 4.5 m in length. Abbreviations: AFLP, amplified fragment-length polymorphism; BoNT, botulinum neurotoxin.
Figure 3. Occurrence and distribution of A(B), bivalent (Ba, Bf) and rare strains of C. botulinum. A, All A(B) California IB patient isolates (n = 66) located to 6 multimember and 5 singleton clades. One California 3-year-old intestinal toxemia patient isolate and 2 WB isolates not depicted. B, The second-largest A(B) clade (n = 23) included 20 California patients and contained a geographic-temporal cluster of 3 patients near Bakersfield. C, BoNT/Ba (n = 17), BoNT/Bf (n = 3) and C. baratii type F (n = 2) California IB patient isolates. D, Clade of 12 BoNT/B, /Ba and /Bf patient isolates. Geographic-temporal clusters determined using the Kulldorff spatial-scan statistic [24]. Abbreviations: BoNT, botulinum neurotoxin; IB, infant botulism; WB, wound botulism.
the Sierra Nevada foothills home of a Madera County type A patient; type A soil isolates from the homes of type A patients in Ontario, California, and Reno, Nevada; and 1 type B soil isolate and 1 ceiling fan dust type B isolate from the home of 2 type B twin patients in Stanislaus County. The 3 exceptions to the clade co-location of patient and environmental isolates consisted of a type A soil isolate and a type B soil isolate from the Alameda County home of the 2 type A sibling patients and 2 type A soil isolates from the homes of 2 Yolo County type A patients.

The Largest BoNT/A Clade

This clade contained 418 isolates from 399 California IB patients (Table 2, #1; Figure 1B), 1 IB patient from Mexico, 4 IB patients from neighboring western states (Idaho, Nevada, Utah, Washington), 5 wound botulism (WB) patients (n = 4 California, n = 1 Utah), 3 honeys, 2 food items (carrots, cow’s liver), 3 soil isolates associated with patients (n = 2 California, n = 1 Nevada), and a Hall strain. All 12 isolates subtyped were bont/A1. Notably, no isolates in this clade were from states east of the Rocky Mountains.

Geospatial analysis of the 387 California IB patient isolates (excluding the 12 sudden-death cases) in this clade identified a geographic cluster centered near Escondido (San Diego County) that contained 27 IB cases (radius approximately 35 km; \( P = 0.005 \)) (Figure 1B). Two other closely related BoNT/A clades (Table 2, #2–3) also contained geographic clusters: 1 clade (n = 12) contained a cluster of 7 isolates centered near Rialto (San Bernardino County) (radius approximately 15 km; \( P < 0.001 \)), and the other clade (n = 70) contained a cluster of 48 isolates (76% of the clade’s IB cases) centered near Napa, north of San Francisco Bay (radius approximately 124 km; \( P < 0.001 \)).
Table 3. Geographical Coordinates of Patient Isolate Clusters

<table>
<thead>
<tr>
<th>AFLP Clade in Figure 2</th>
<th>Figure/Panel</th>
<th>Where_mapped</th>
<th>Cluster Center, Lat/Long</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Largest BoNT/A</td>
<td>1/B</td>
<td>33.12, −117.06</td>
<td></td>
</tr>
<tr>
<td>2. Southern California A closely related to above largest BoNT/A</td>
<td>N/A</td>
<td>34.11, −117.38</td>
<td></td>
</tr>
<tr>
<td>3. Northern California A closely related to above largest BoNT/A</td>
<td>N/A</td>
<td>38.31, −122.32</td>
<td></td>
</tr>
<tr>
<td>4. Northern California BoNT/A</td>
<td>4/A</td>
<td>38.63, −121.22</td>
<td></td>
</tr>
<tr>
<td>5. Largest A(B)</td>
<td>N/A</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>6. Central Valley A(B)</td>
<td>3/B</td>
<td>35.32, −119.09</td>
<td></td>
</tr>
<tr>
<td>7. Largest BoNT/B</td>
<td>1/D</td>
<td>33.83, −117.98</td>
<td></td>
</tr>
<tr>
<td>8. Primarily Southern California BoNT/B closely related to the largest BoNT/B clade</td>
<td>N/A</td>
<td>34.16, −118.13</td>
<td></td>
</tr>
<tr>
<td>9. East San Francisco Bay area BoNT/B</td>
<td>4/B</td>
<td>37.73, −121.44</td>
<td></td>
</tr>
<tr>
<td>11. Southern California BoNT/B</td>
<td>N/A</td>
<td>34.06, −118.43</td>
<td></td>
</tr>
<tr>
<td>12. Primarily 2000s BoNT/B</td>
<td>4/D</td>
<td>34.43, −118.47</td>
<td></td>
</tr>
<tr>
<td>13. BoNT/B, BoNT/Ba, BoNT/Bf</td>
<td>3/D</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>14. Primarily Mid-Atlantic BoNT/B</td>
<td>N/A</td>
<td>ND</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: AFLP, amplified fragment-length polymorphism; BoNT, botulinum neurotoxin; Lat/Long, latitude/longitude; N/A, not applicable; ND, not determined.

The Largest BoNT/B Clade

This clade (Table 2, #7; Figure 1D) contained 145 isolates, 142 of which were from California IB patients, including 1 outpatient and 1 sudden-death case. The single strain in the clade not from California was isolated in 1979 from the first-recognized IB patient in the Czech Republic [31]. All 6 isolates subtyped were bont/B1. This clade contained a geographic cluster in Southern California centered near Anaheim (Los Angeles County) (radius approximately 39 km; P = .001) that contained 71 (50%) of the clade’s California IB patients.

A(B) Strain Clades

The analysis identified 86 C. botulinum A(B) isolates (66 from California IB patients and 14 from IB patients in Alaska, Arkansas, Colorado, Georgia, Illinois, Nevada, New Mexico, Oklahoma, Texas, Washington, and Wyoming). Such A(B) strains were not previously known to exist in California (Table 2, #6; Figure 3A). The A(B) isolates located to 14 clades (7 multimenber clades and 7 singleton clades); 5 clades contained non-California A(B) strains, and 2 contained both A(B) and type B strains. A(B) strains were isolated in California in all years of the study period except 1976, 1978, 1983, and 1995 (Figure 3A). The largest A(B) clade (n = 43) contained isolates from 31 California IB patients, 8 other US IB patients, 1 Canada IB patient, 2 California WB patients and the National Collection of Type Cultures reference strain NCTC 2916 (Table 2, #5). This clade had no geographic clusters in California, whereas the second-largest A(B) clade (Table 2, #6) contained a geographic-temporal cluster from 2006 to 2009 centered in California’s Central Valley near Bakersfield (Kern County) (radius approximately 8 km; P = .047) that contained 3 IB cases (Figure 3B).

Bivalent (Ba, Bf) Clades

The molecular analysis identified 17 bivalent B5a4 isolates that located to 5 clades and 4 B5f isolates, 3 from California and 1 from Texas, that located to 3 clades. The largest of the bivalent clades (Table 2, #13) notably contained several B5 and B5a4 isolates and 1 B5f isolate (Figure 3D). A single unique strain that contained a bont/A5 gene and a partial bont/B gene [the bont/A5/B3′ gene arrangement [9]] that was isolated from a San Diego County IB patient located to a singleton clade.

Mid-Atlantic US Type B Clades

Two clades of BoNT/B patient isolates mapped mainly to certain areas in the eastern Mid-Atlantic United States. The first clade (n = 8) included the 1939 Tennessee BoNT/B1 Okra reference strain [32], 3 patients from Maryland, and 1 patient each from New Jersey, Pennsylvania, Alabama, and California. The California IB patient was born prematurely and had not been discharged from her birth hospitalization before onset of illness. However, some of the specialty formulas fed to her were produced in the Mid-Atlantic region; although these formulas tested negative for C. botulinum, 1 contained C. sporogenes. The second Mid-Atlantic BoNT/B clade (Table 2, #14) contained 11 bont/B1 isolates: 8 IB patients from either New Jersey, New York, or Pennsylvania; 1 patient from Colorado; and 2 patients from California and Oregon who had traveled to New York City and Pennsylvania, respectively, in the month before onset of illness. Geographical clustering in these clades could not be evaluated because the reference set of East Coast patient isolates was too small.

Other Noteworthy California Clades

Five additional California clades demonstrated either geographic or geographic-temporal clustering. A BoNT/A clade with 23 California IB patient and 5 environmental isolates (Table 2, #4; Figure 4A) had a geographic-temporal cluster of 7 patients from 2005 to 2008 centered northeast of Sacramento (radius approximately 101 km; P = .003).

The second clade, BoNT/B with 10 IB patient and 1 soil isolate (Table 2, #9; Figure 4B), had a geographical cluster of 9 patient isolates that centered east of San Francisco Bay (radius of approximately 69 km; P = .002). The third clade, BoNT/B with 30 California IB patient isolates, contained a geographic-temporal cluster from 1992 to 1994 in southern California with 18 patient isolates centered in the San Fernando Valley (Los Angeles County) (radius approximately 97 km; P < .001) (Table 2, #10; Figure 4C). The fourth clade of 12 BoNT/B California patients...
Figure 4. Geographic and geographic-temporal clusters of California IB cases between 1976 and 2010. A, BoNT/A clade of 23 patient isolates with a geographic-temporal cluster centered near Sacramento. This clade also contained 1 vacuum cleaner dust and 2 soil isolates (not shown). B, BoNT/B clade of 10 California patient isolates that clustered in the east San Francisco Bay area. The sole outlier patient lived in a central coastal county, had not traveled, and had been fed nonsterile solid foods. This BoNT/B clade also contained 1 soil isolate (not shown) from a patient home in an eastern San Francisco Bay city. C, BoNT/B clade of 30 California patient isolates with a geographic-temporal cluster that occurred in southern California, 1992–1994. Note the absence of this particular C. botulinum type B strain in California patients before 1992 and after 1999, with 97% of the cases in the clade having occurred in the 4 years 1992–1994. D, BoNT/B clade of 10 California IB patient isolates with a geographic-temporal cluster in southern California (1 WB patient from 1999 not shown). All IB cases occurred in 2008–2009 except for the 1986 case, who was driven through the Los Angeles basin (center of cluster) 2 weeks before onset of illness when the family moved from San Diego County to the San Francisco Bay area. Geographic-temporal clusters were determined using the Kulldorff spatial-scan statistic [24]. Abbreviations: BoNT, botulinum neurotoxin; IB, infant botulism; WB, wound botulism.
that also clustered in southern California both temporally (1980–1983) and geographically was centered near Pasadena (radius approximately 30 km; \(P = .015\)) (Table 2, #8).

The fifth clade, BoNT/B with 10 IB and 1 WB patient isolates (Table 2, #12; Figure 4D), contained a 2008–2009 geographic-temporal cluster of 6 patient isolates centered in the Santa Clarita Valley (Los Angeles County) (radius approximately 68 km; \(P < .001\)). Nine of 10 IB patients in this clade became ill in 2008–2009; in 1986, the tenth patient became ill 2 weeks after traveling through the Los Angeles basin (the center of the cluster).

DISCUSSION

The Infant Botulism Treatment and Prevention Program (IBTPP) collection of neurotoxicogenic clostridial strains provided a unique opportunity to combine molecular and epidemiological information to better understand IB in California. Significant novel findings of this endeavor included: (1) the identification of 2 large clades that contained endemic strains that caused more than half of the BoNT/A and more than one-third of the BoNT/B IB cases in California in the 35-year study period; (2) the co-location of patient isolates from all 3 segments of the IB clinical spectrum (outpatient, hospitalized, sudden death) to the same BoNT/A or BoNT/B clade; (3) the identification of \(C.\) botulinum A(B) isolates in IB patients from California and 11 other US states that would not have been identified by the mouse neutralization assay; (4) the identification of rare strains isolated from 25 IB and 2 adult botulism cases that include BoNT/B5a4 (\(n = 17\)), BoNT/Bf (\(n = 4\)), and \(C.\) baratii BoNT/F (\(n = 6\)) isolates; (5) the recognition of clades whose isolates share a common-source origin (eg, honey); (6) the identification of clades whose isolates are restricted geographically to limited areas of California; and (7) the co-location to the same clade of \(C.\) botulinum patient and associated dust, soil, and honey isolates that could cause IB when swallowed by susceptible infants. The extensive branching of the dendrogram displays and emphasizes the different genetic backgrounds of \(C.\) botulinum strains that express the same toxin types.

\(C.\) botulinum type A(B) isolates have been reported from Alaska, Arizona, Colorado, Georgia, Illinois, Louisiana, Nebraska, New Mexico, Pennsylvania, Puerto Rico, Wisconsin, and West Virginia \([29, 33–35]\). In this study, \(A(B)\) isolates were newly identified in IB patients from Arkansas, California, Nevada, Oklahoma, Texas, Washington, and Wyoming, further suggesting that \(A(B)\) strains are widespread throughout the United States. The molecular analysis and mouse neutralization assay also identified 17 bivalent BoNT/B5a4 and 3 BoNT/Bf isolates that caused IB in California. Recognition of BoNT/B5a4 strains outside of California that cause IB has occurred infrequently; only the 1976 Texas \([36–38]\) and 1999 Texas and 2006 Nevada patients reported in the CDC annual national botulism surveillance summaries were previously known.

The AFLP analysis also identified clades that contained isolates associated with honey exposure or that contained geographic-temporal clustering. The 4 patients in the only \(bont/A2\) clade were fed honey; the clade also contained a \(bont/A2\) isolate from a honey consumed by 1 of the patients. The BoNT/A2 subtype had previously been isolated only from Argentinian soils and from IB patients in Argentina \([39]\), Italy \([33]\), and Japan who were fed honey \([40]\), as well as from a Brazilian honey \([40]\) and from honey \([41]\) fed to a New Jersey patient that may have contained blended imported Argentinian honey. Because honey may harbor \(C.\) botulinum spores, all major public health, pediatric, and honey-producing institutions have recommended that honey not be fed to infants \([42]\).

Three clusters within California BoNT/B clades occurred in limited time spans: 1 in 1992–1994 (Figure 4C), 1 in 2008–2009 (Figure 4D), and 1 in 1983–1985 (not shown). The latter occurred in a clade of monovalent BoNT/B5 isolates associated with honey exposure; interestingly, no monovalent BoNT/B5-producing isolates have been identified in California since 1988. No common-source exposures to a food or environmental source were identified for the temporal clusters in the 2 other BoNT/B clades. Possible sources of exposure to \(C.\) botulinum spores include nonsterile infant foods (eg, powdered infant formulas, dry cereals, herbal teas \([43–45]\)), and anthropomorphic activities or weather phenomena that disrupt surface soil \([46, 47]\).

Geographical localization of isolates in some clades (Figures 1, 3, and 4) suggests that local soil and/or climatic conditions may contribute to multiplication and subsequent dissemination of \(C.\) botulinum spores. Notably, isolates from several patients and their home environments (dust/soil, honey) located to the same clade. Soil surveys in Argentina \([48]\) and the United States \([49]\) have reported differing prevalences and BoNT types in different geographic regions. In the United States, BoNT/A strains predominate in soils west of the Mississippi River, while BoNT/B strains predominate in soils east of the Mississippi River; this regionalization matches the nationwide distribution of IB patient toxin types \([22]\). Our geographic-temporal analyses found that IB isolates from certain clades concentrated in specific geographical areas; for example, a BoNT/A clade northeast of Sacramento (Figure 4A), a BoNT/B clade in the San Francisco Bay area (Figure 4B), and a BoNT/B clade in the Santa Clarita Valley (Figure 4D). Two clades of BoNT/B isolates from patients who resided primarily in the Mid-Atlantic United States or had recently traveled there were also identified. These examples suggest that IB may be acquired from the local environment or while traveling in endemic areas.

In conclusion, the molecular analyses provided new and useful information for elucidating epidemiological relationships and for differentiating \(C.\) botulinum isolates. The study resulted
in an AFLP dendrogram of 1091 isolates that displays the genetic and epidemiological complexity of neurotoxicogenic clostridia (Figure 2 and Supplementary Data Appendix 1). Importantly, the geographical clustering of isolates was identified by use of patient epidemiological information. The combination of molecular methods and epidemiological data created an effective tool that yielded novel insights into the genetic diversity of \textit{C. botulinum} and the clinical spectrum, occurrence, and distribution of IB in California.

**Supplementary Data**

Supplementary materials are available at The Journal of Infectious Diseases online (http://jid.oxfordjournals.org). Supplementary materials consist of data provided by the author that are published to benefit the reader. The posted materials are not copyedited. The contents of all supplementary data are the sole responsibility of the authors. Questions or messages regarding errors should be addressed to the author.

**Notes**

Acknowledgments. We especially thank the many former IBTPP epidemiologists for carefully collecting IB patient information. We also thank Theresa Smith, US Army Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, MD, for assistance in identifying the origins of certain reference strains and USAMRIID for permission to compare the AFLP patterns of its \textit{C. botulinum} strains to the AFLP patterns of IBTPP strains. The Microbial Disease Laboratory, CDPH, isolated and generously provided the 12 California WB isolates. The type E reference strain K112 published by Hyytiä et al in 1999 [50] was an earlier gift to CDPh from the Food Research Institute, University of Wisconsin-Madison.

The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Los Alamos National Laboratory or the California Department of Public Health.

Financial support. The RT-PCR assay development work was supported by the US Department of Homeland Security Science and Technology Directorate. This work was otherwise supported by the Infant Botulism Treatment and Prevention Fund of the California Department of Public Health.

Potential conflicts of interest. All authors: No potential conflicts of interest.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

**References**


